SEC Form 4
Eton Pharmaceutcials, Inc. (ETON) insider trading
In the 12 months to Oct 26, 2026, 5 ETON insiders reported open-market sales of $25.4M across 9 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $25.4M
- 9 filings · 5 insiders
- Open-market purchases
- $0
- 0 filings
Who traded ETON, and when
- Sale
ETON daily close from Oct 27, 2025 to Oct 26, 2026, between $14.35 and $64.43, last $50.88. 9 sale and 0 purchase filings by 5 insiders, marked at their filing dates. Sean Brynjelsen, President & CEO: sold $9.9M across 2 filings, first filed May 29, 2026, last Aug 20, 2026. Opaleye Management Inc., 10% owner: sold $5.8M across 2 filings, first filed Jul 7, 2026, last Jul 17, 2026. David Krempa, Chief Business Officer: sold $5.1M across 3 filings, first filed May 27, 2026, last Oct 6, 2026. Paul V. Maier, Director: sold $3.0M across 1 filing, first filed Aug 31, 2026, last Aug 31, 2026. Jennifer McKie Adams, Director: sold $1.6M across 1 filing, first filed Jun 17, 2026, last Jun 17, 2026.
Largest mark · tap a row for others
Sean Brynjelsen · President & CEO
Sale $6,087,773
100,000 shares at $60.88 avg
Filed Aug 20, 2026 · traded Aug 19
Close on filing date $59.91
Sean Brynjelsen · President & CEO
President & CEO
$9.9M soldOpaleye Management Inc. · 10% owner
10% owner
$5.8M soldDavid Krempa · Chief Business Officer
Chief Business Officer
$5.1M soldPaul V. Maier · Director
Director
$3.0M soldJennifer McKie Adams · Director
Director
$1.6M soldOpen-market trades
9 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Sean Brynjelsen | President & CEO | $9.9M | — | 2 | — | |
| Opaleye Management Inc. | 10% owner | $5.8M | — | 2 | — | |
| David Krempa | Chief Business Officer | $5.1M | — | 3 | — | |
| Paul V. Maier | Director | $3.0M | — | 1 | — | |
| Jennifer McKie Adams | Director | $1.6M | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | David Krempa Chief Business Officer | Sale | 4,166 | $55.07 | $229.4K | 43,381 | |
traded | Paul V. Maier Director | Sale | 50,000 | $59.07 | $3.0M | 59,873 | |
traded | David Krempa Chief Business Officer | Sale | 25,000 | $65.07 | $1.6M | 37,025 | |
traded | Sean Brynjelsen President & CEO | Sale | 100,000 | $60.88 | $6.1M | 1,004,909 | |
traded | Opaleye Management Inc. 10% owner | Sale | 28,315 | $37.54 | $1.1M | Multiple accounts | |
traded | Opaleye Management Inc. 10% owner | Sale | 126,685 | $37.64 | $4.8M | Multiple accounts | |
traded | Jennifer McKie Adams Director | Sale | 50,000 | $32.48 | $1.6M | 0 | |
traded | Sean Brynjelsen President & CEO | Sale | 120,000 | $31.88 | $3.8M | 833,842 | |
traded | David Krempa Chief Business Officer | Sale | 100,000 | $32.30 | $3.2M | 25,249 |
GET /stocks/filings/vX/form-4?tickers=ETON&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ETON"
],
"issuer_cik": "0001710340",
"owner_cik": "0001968254",
"accession_number": "0001437749-26-032240",
"form_type": "4",
"filing_date": "2026-10-06",
"period_of_report": "2026-10-06",
"issuer_name": "Eton Pharmaceuticals, Inc.",
"issuer_trading_symbol": "ETON",
"owner_name": "Krempa David",
"is_officer": true,
"officer_title": "Chief Business Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-10-06",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 4166,
"transaction_price_per_share": 55.0663,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 43381,
"transaction_value": 229406.2058,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price."
},
{
"id": "F2",
"description": "The shares were sold in multiple trades at prices ranging from $54.915 to $55.135. The price reported above reflects the weighted average sales price."
}
],
"remarks": "The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration."
},
{
"tickers": [
"ETON"
],
"issuer_cik": "0001710340",
"owner_cik": "0001182615",
"accession_number": "0001437749-26-029308",
"form_type": "4/A",
"filing_date": "2026-08-31",
"period_of_report": "2026-08-28",
"issuer_name": "Eton Pharmaceuticals, Inc.",
"issuer_trading_symbol": "ETON",
"owner_name": "MAIER PAUL V",
"is_director": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-28",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 128,
"transaction_price_per_share": 61.77,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 59745,
"transaction_value": 7906.56,
"date_of_original_submission": "2026-08-28",
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price."
},
{
"id": "F5",
"description": "The shares were sold in multiple trades at prices ranging from $61.10 to $61.98. The price reported above reflects the weighted average sales price."
}
],
"remarks": "The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration."
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 23 records
- Option exercises15 records
- Tax withholding7 records
- Other1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Eton Pharmaceutcials, Inc.'s CEO sold stock?
Yes. Sean Brynjelsen (CEO) sold 220,000 shares ($9.9M) between May 2026 and Aug 2026.
How current is ETON’s insider data?
These are ETON Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ETON insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ETON every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.